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Summary
Objective: To characterize and validate a novel enzyme-linked immunoassay for measuring cross-linked dimer forms of C-terminal telopep-
tides of type II collagen (CTX-II) in serum and synovial ﬂuid of rodents, and investigate whether CTX-II measurements can reﬂect joint status in
two established animal models of destructive joint diseases.
Methods: Firstly, the speciﬁcity, in vivo validity, antigen recovery, and reproducibility of the assay were investigated. Secondly, we induced
arthritis in rats using either bovine collagen type II or mono-iodoacetate. CTX-II levels were measured in the serum and synovial ﬂuid of
the affected femoro-tibial joint and correlated with microscopic severity of joint lesions as determined by validated scoring systems.
Results: The F4601 monoclonal antibody (mAb) is highly speciﬁc for the EKGPDP sequence at the CTX-II. Strong CTX-II signals were de-
tected during enzymatic degradation of articular cartilage explants by matrix metalloproteinase (MMP)-9 or MMP-13. The assay presented
a good degree of precision and reproducibility (inter- and intra-assay coefﬁcient of variations< 8.0%). In the collagen-induced arthritis
(CIA) model, the assay indicated markedly increased levels of CTX-II in both the synovial ﬂuid and the serum. Furthermore, CTX-II levels
in both the synovial ﬂuid (r¼ 0.76; P< 0.0001) and the serum (r¼ 0.85; P< 0.0001) showed strong correlations with the microscopic severity
scores of joint lesions at Day 22. In the mono-iodoacetate-induced arthritis (MIA) model, CTX-II concentration in the synovial ﬂuid (r¼ 0.53;
P< 0.0001), but not in the serum, correlated with the microscopic severity score.
Conclusions: The Preclinical CTX-II assay could provide a useful supplement to currently available methods for the non-invasive assessment
of cartilage status. The utility of serum CTX-II to reﬂect joint status appeared to be limited to systemic forms of destructive joint diseases.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: CIA type II collagen-induced arthritis, MIA mono-iodoacetate-induced arthritis, CTX-II collagen type II C-telopeptide degrada-
tion fragment, OA osteoarthritis, RA rheumatoid arthritis, COMP cartilage oligomeric matrix protein, MMP matrix metalloproteinase, CV coef-
ﬁcient of variation.Introduction
Currently, there are numerous animal models available for
preclinical research aiming for the better understanding of
the pathophysiology, diagnostics, and treatment options of
destructive joint diseases, such as rheumatoid arthritis
(RA) and osteoarthritis (OA). Due to similar pathology and
the presence of collagen type II-reactive T and B lympho-
cytes, the rat model of collagen-induced arthritis (CIA) is
one of the most widely used models of RA1e4. OA can be
induced by diverse ways, such as anterior cruciate ligament
transection5,6, ovariectomy7, or intra-articular injection of
mono-iodoacetate8e10.
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modifying agents on arthritis and related structural alterations
of affected joints, we need to sacriﬁce the experimental
animals and directly grade the microscopic structural changes
in the affected joint. Non-invasive techniques reliably reﬂect-
ing structural changes of articular cartilage remain sparse.
Measurement of different degradation products of the
cartilage matrix in synovial ﬂuid may solve some of these
problems, yet this approach is not ideal for monitoring pur-
poses due to limited sample volume and major difﬁculties
with obtaining serial samples. Therefore, there is a need
for biochemical markers that are detectable in the serum
and could ease the aforementioned technical difﬁculties
for researchers.
In the past years, numerous biochemical markers have
been developed and tested for their ability to serve such pur-
poses. Of the different marker candidates, the cartilage olig-
omeric matrix protein (COMP)11,12 and the C-terminal
telopeptide of collagen type II (CTX-II)4 have yielded70
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ies using the meniscectomy-induced OA model have dem-
onstrated a signiﬁcant correlation between CTX-II
concentration in the synovial ﬂuid (estimated by variant as-
say, Col2CTx) and the severity of OA graded by histological
evaluation of articular cartilage13,14. The potentials of CTX-II
are also corroborated by observations indicating that early
changes in urinary excretion of CTX-II in ovariectomized
rats show a signiﬁcant correlation with subsequent structural
changes of articular cartilage7,15. These experimental obser-
vations are corroborated by clinical ﬁndings indicating that
urinary CTX-II is elevated in patients with RA and OA com-
pared with healthy individuals, and levels of the biomarker
are predictive for the rate of cartilage degradation16e21. Se-
rial measurements of CTX-II can be helpful in monitoring
the effect of potential disease-modifying drugs22,23.
Herein we introduce a novel immunoassay, which targets
cross-linked forms of CTX-II and allows measurements in
both synovial ﬂuid and serum samples from rodents. In ad-
dition to the standard technical validation of the assay, we
demonstrate the utility of CTX-II measurements for reﬂect-
ing structural alterations of articular joints in two well-
established models of RA and OA, namely, the CIA and
the mono-iodoacetate-induced arthritis (MIA), respectively.
Materials and methods
PART 1: IN VITRO TECHNICAL VALIDATION
Reagents
All chemicals were standard high-quality reagents from
either Sigma or Merck (Darmstadt, Germany), unless other-
wise stated. The phosphate buffer solution (PBS) used in
the different experiments had a composition as follows:
(1) coating buffer and standard buffer: 7.35 mmol/L
KH2PO4, 40 mmol/L Na2HPO4 2H2O, 2.7 mmol/L KCl,
137 mmol/L NaCl, 10 g/L bovine serum albumin (BSA),
0.18 g/L Bronidox (Henkel, Germany), 25 mmol/L ethylene-
dinitrilotetraacetic acid (EDTA), and 1.1 g/L Tween 20,
0.03 g/L phenol red, pH 7.0; (2) incubation and peroxidase
(POD) buffer: coating buffer plus 5% Liquid II (blocking
buffer, cat no. 119941736-001, Roche, Germany), and
0.03 g/L bromphenol blue, pH 7.0; and (3) washing buffer:
25 mmol/L Tris, 50 mmol/L NaCl, 1 g/L Tween 20, pH 7.2.
Preparation of monoclonal antibodies
The monoclonal antibody (mAb) F4601 (subclass IgG1k)
was prepared exactly as described previously in detail16.
The mAbF4601 was chosen because of its better stability
data compared with F26.
Determination of antibody’s specificity
Solutions of eight different peptides (KGPDP, KGPDPL,
EKGPD, REKGPD, REKGPDP, EKGPDP, EKGPDPL and
DEKAGGAQ (Chimex Ltd, St. Petersburg, Russia)) in the
concentration range from 1010 to 104 M were used for
the assessment of the speciﬁcity of the mAbF4601. The
Enzyme-linked immunosorbent assay (ELISA) used for
these experiments had a competitive format.
Assay for detection of CTX-II fragments in serum
or synovial fluid
Biotinylated F4601 antibodies were diluted in coating
buffer (100 mL, 500 mg/L) and pipetted into wells ofa streptavidin-coated micro-titre plate (Roche, Germany).
Subsequently, the plates were placed on a mixing appara-
tus and subjected to shaking at 3000 rpm while incubated
for 30 5 min at 18e22(C (all subsequent incubations
were performed under identical conditions). Thereafter,
the plates were washed with buffer ﬁve times. Twenty-ﬁve
microlitres of the calibrator, control, or unknown serum sam-
ple was pipetted into the appropriate micro-titre wells fol-
lowed by addition of 100 mL incubation buffer. After
incubation for 60 5 min and washing, 100 mL of peroxi-
dase-conjugated mAbF4601 (diluted in POD buffer) was pi-
petted into each well. Following incubation for another
60 5 min, the wells were emptied, after which 100 mL of
3,30,5,50-tetramethylbenzidine solution (Kierkegaard &
Perry, Gaithersburg, MD) was added to each well. After
15 min of incubation in darkness, the colour reaction was
stopped by addition of 100 mL of 0.18 mol/L H2SO4. The
spectrophotometric absorbance was measured at 450 nm,
with 650 nm as the reference wavelength, using a micro-
titre plate reader (Molecular Devices, USA).
Fetal calf serum (FCS) containing a native molecule of C-
telopeptide fragment of collagen type II was chosen as
standard. FCS was diluted in standard buffer (zero calibra-
tor) and standards were prepared covering a range from
0 to 270 ng/L. The standard curve was calibrated by reading
the standards on a calibration curve prepared with synthetic
dipeptide, i.e., EKGPDPeEKGPDP (3-succinyl linked K,
High Performance Liquid Chromatography (HPLC)
purity> 95%, Pepceuticals Ltd, UK). To increase stability,
the standards were freeze-dried and stored at 4(C.
Enzymatic assays for collagen type II degradation
All reactions were investigated in 0.5 ml of the matrix met-
alloproteinase (MMP) buffer (50 mM TriseHCl buffer (pH
7.5), 10 mM CaCl2, 150 mM NaCl and 0.05% Brij 35). Sam-
ples of 2e3 mg articular cartilage taken from the stiﬂe joint
of 9-month-old cows were submerged in liquid nitrogen
and defrosted (three repeated cycles). Subsequently, the
tissue samples were washed three times in MMP buffer.
The MMP-9 and MMP-13 (R&D Systems, USA) enzymes
were activated by co-incubation with 1 mM APMA (p-ami-
nophenylmercuric acetate) for 24 h at 37(C. After activa-
tion, 10 mL of the enzyme suspension was added to
a 0.490 ml aliquot of the cartilage suspension giving a ﬁnal
MMP concentration of 20 nM. Incubation was performed in
triplicates for 24 h at 37(C under gentle shaking. At the end
of the incubation, the reaction was stopped by addition of
10 mL of 10 mM GM6001 (Ilomastat, AMS Scientiﬁc,
USA). The supernatants were collected and kept at
80(C until assaying by the novel immunoassay. To inves-
tigate the role of MMPs in the generation of CTX-II frag-
ments, the tissue samples were incubated under the
following conditions: (1) incubation in MMP buffer only (neg-
ative control), (2) incubation with MMPs, (3) incubation in
the simultaneous presence of MMPs and the MMP inhibitor
(GM6001), or (4) incubation with the MMP inhibitor only.
Lowest detection limit, intra- and inter-assay
coefficient of variations (CVs), and linearity
These assay parameters were determined as described
earlier by Christgau et al.16. In brief, the detection limit
was deﬁned as the concentration corresponding to 3 SD
above the mean of 21 determinations of the zero calibrator.
Intra- and inter-assay CVs were assessed by the measure-
ment of 10 serum samples in 10 consecutive analytical
runs, each sample measured in duplicates. Measurements
672 S. Oestergaard et al.: CTX-II and cartilage damageof diluted serum samples assessed the linearity of the CTX-II
immunoassay. Dilution was performed in increments of 20%.
Dilution recovery was expressed as percentage of the
theoretically expected values. Analytical recovery was
performed by spiking standards into serum samples and
spiking a serum sample into another serum sample.
PART 2: IN VIVO BIOLOGICAL VALIDATION
Animals
Forty-six 8-week-old female Lewis (LEW/SsN/CrCrlBR)
and 59 8-week-old male SpragueeDawley CD (Crl:CD
(SD)BR) rats were obtained from Charles River Canada
Inc. (Quebec, Canada). The animals were housed (2e3
per cage) in a room maintained at 22 3(C, subjected to
12-h/12-h light/dark cycles and given food (RPR 5L35,
PMI Nutrition International Inc., USA) and water ad libitum.
All experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) and were performed ac-
cording to the guidelines of the USA National Research
Council and the Canadian Council on Animal Care
(CCAC) and in accordance with the United States Food
and Drug Administration, Good Laboratory Practice Regula-
tions (21 CFR Part 58).
Study design
Allocation of the animals to the different intervention
groups of the CIA and MIA cohorts is illustrated in Table I.
For the CIA model, two cohorts were initiated to assess
the joint lesions at two distinct time points, i.e., Day 22
and Day 28. For induction of CIA, bovine type II collagen
(Chondrex Inc., Redmond, WA, USA) emulsiﬁed in an equal
volume of incomplete Freund’s adjuvant (Sigma Chemicals
Co., St. Louis, MO, USA) was used. All rats in Groups 2 and
3 were immunized twice e on Day 1 (200 mL) and Day 8
(100 mL) e by subcutaneous injection to the base of the
tail. The control group (Group 1) received saline injection.In Groups 5 and 6 of the MIA cohort, arthritis was induced
by injecting 0.25 mg mono-iodoacetate (Sigma Chemicals
Co., St. Louis, MO, USA) dissolved in 0.025 ml saline to
the right femoro-tibial joint. The respective control animals
(Group 4) received injection of saline in identical volume.
Dexamethasone treatment of Group 3 was initiated at the
onset of the disease (deﬁned as mild, but deﬁnite redness
and/or swelling of at least one joint), whereas doxycycline
treatment of Group 6 was initiated on the day of the disease
induction and was continued twice daily for 7 days. Both
treatments were administered as oral gavage.
On the day of termination (Day 22 or Day 28), the ani-
mals’ blood was collected from the abdominal aorta using
a syringe. Simultaneously, synovial ﬂuid was collected
from both femoro-tibial joints using a ﬁne needle syringe
ﬁlled with 200 mL saline. Prior assaying, synovial ﬂuid sam-
ples were incubated overnight at 37(C in the presence of
5 units/ml hyaluronidase24.
Macroscopic and microscopic evaluations
of joint lesions
The macroscopic severity score was focused on inﬂam-
matory signs, such as redness and swelling, which were
graded on a semi-quantitative scale from 0 to 4 (0: normal;
1: mild, but deﬁnite redness and/or swelling of the ankle or
wrist, or apparent redness and/or swelling limited to individ-
ual digits, 2: moderate redness and/or swelling of ankle or
wrist; 3: severe redness and/or swelling of the entire hind
paw including digits; 4: maximally inﬂamed limb with
involvement of multiple joints). This evaluation was per-
formed in rats with CIA only. Given the systemic nature of
the disease, the scoring included the radio-carpal, femoro-
tibial, tibio-tarsal and tarsal joints of both sides.
Microscopic evaluation in rats with CIA was performed at
femoro-tibial and tarsal joints. In rats with MIA, the scoring
was focused on the injected femoro-tibial joint. The respec-
tive joints were collected and retained in 10% formalin. The
joints were decalciﬁed in formic acid, dehydrated throughTable I
Study design
CIA model
Group no. identiﬁcation Induction of arthritis Intervention given
for 6 days
Number of females
Day 22 stopped Day 28 stopped
(1) Negative control
A Saline Saline 10
B Saline Saline 10
(2) Positive control
A Bovine CII Saline 9
B Bovine CII Saline 9
(3) Treated group Bovine CII Dexamethasone
0.025 mg/kg/day
8
MIA model
Group no. identiﬁcation Induction of arthritis Control article Number of males
Day 22 stopped
(4) Negative control Saline Deionised water 19*
(5) Positive control Mono-iodoacetate Deionised water 20*
(6) Treated group Mono-iodoacetate Doxycycline 10 mg/kg/day 20*
CII denotes collagen type II.
*From Groups 4, 5 and 6 only 13, 14 and 15 animals, respectively, underwent microscopic scoring.
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afﬁn. Two sections were cut: one was stained with Safranin-
O and the other with haematoxylin and eosin. The severity
of the joint damage was assessed microscopically for the
presence of cartilage damage (ﬁbrillations/erosions/clefts,
chondrocyte necrosis, proteoglycan loss), subchondral
bone resorption, osteophytes, and inﬂammation. Severity
of each lesion was graded semi-quantitatively on a scale
from 0 to 5 (0: no change, 1: minimal, 2: slight, 3: moderate,
4: severe, 5: massive). Subcores of the individual lesions
were summarized in a total score. The same investigator,
who was blinded for treatment codes, performed the scoring
of the histological sections. A more detailed description of
the used method can be found elsewhere25e27.
STATISTICAL ANALYSIS
Differences between means of the different study param-
eters were compared with KruskaleWallis test followed by
pair wise comparison of selected groups with ManneWhitney
test. Correlations of CTX-II in the serum and synovial ﬂuid
with microscopic severity scores of joint lesions were
assessed using the Spearman’s rank correlation analysis.
Differences and associations were considered as statisti-
cally signiﬁcant, if P< 0.05.
Results
PART 1: IN VITRO TECHNICAL VALIDATION
Antibody’s specificity
A 50% inhibition of the ELISA signal was obtained in the
presence of 90 nmol/L CTX-II peptide (EKGPDP). Extend-
ing the peptide with one N-terminal amino acid (REKGPDP)
produced a similar inhibition curve. The peptide KGPDP,
truncated at the N-terminal end, yielded a 50% inhibition
of the ELISA signal at a concentration of 5 mmol/L. Neither
the peptides EKGPDPL and KGPDPL (both being extended
with one Leucin at the C-terminal), nor the peptides EKGPDand REKGPD (both lacking a free C-terminal Prolin) could
inhibit the signal when investigated in concentrations up
to 100 mmol/L. The mAbF4601 antibody was not reacting
with the peptide DEKAGGAQ derived from the N-terminal
telopeptide of type II collagen (Fig. 1).
CTX-II is generated by MMP-9 and MMP-13
Addition of MMP-9 and MMP-13 to articular explants re-
sulted in rapid induction of collagen type II degradation
and release of epitopes, which were detectable by the
CTX-II assay. The release of these epitopes and hence
the signal detected by the assay could be blocked by addi-
tion of an MMP inhibitor, GM6001 (Table II).
Assay performance
The calibration curve showed good linearity in the range
from 0 to 270 ng/L. The lowest detection limit was 1.1 ng/L.
Both intra- and inter-assay CVs were below 8.0%. The dilu-
tion recovery was in the range 83e106% with an overall
mean of 99% (Table III). Similar good recoveries were
found when spiking standards into serum samples or
when spiking a serum sample into another serum sample
(Table IV).
PART 2: IN VIVO BIOLOGICAL VALIDATION
Collagen-induced arthritis
Macroscopic and microscopic evaluations of joint lesions.
Animals in Groups 1A and 1B showed no signs of inﬂamma-
tion in any of the assessed joints. In contrast, immunization
of rats belonging to Groups 2A and 2B provoked pro-
nounced local inﬂammation causing redness and swelling
of the soft tissue around the joints. These inﬂammatory
signs were present in the tibio-tarsal and tarsal joints of all
animals (9/9), and seven of the nine animals showed it in
the femoro-tibial joint. Inﬂammation at the radio-carpal joint
was present in one animal. Treatment with dexamethasone1E-11 1E-10 1E-09 1E-08 1E-07 1E-06 1E-05 1E-04 1E-03
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Fig. 1. Binding speciﬁcity of the mAbF4601. Speciﬁcity was evaluated by measuring synthetic peptides mimicking different parts of the
C-terminal telopeptide in the a1-chain of human type II collagen, and one peptide speciﬁc for the N-terminal telopeptide (DEKAGGAQ). For all
measurements, a competitive ELISA was used.
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The release of CTX-II from cartilage explants under various experimental conditions evaluated by the CTX-II assay
CTX-II release (pg/ml)
 enzyme þ MMP-9 þ MMP-13
 GM6001 þ GM6001  GM6001 þ GM6001  GM6001 þ GM6001
4.9 3.2 1.6 0.5 1334.9 211.1 1.4 1.0 4475.7 852.2 5.4 5.4
Addition of MMP-9 and MMP-13 resulted in the release of degradation products detectable by the assay. The enzymatic degradation could
be blunted by simultaneous addition of an MMP inhibitor, GM6001. Results shown are mean value S.E.M.(Group 3) did not lower the macroscopic severity scores
compared to the positive control group (Group 2). Thus,
the mean macroscopic severity scores at the day of disease
onset for the three intervention groups were as follows: 0 for
negative control group (Group 1A); 2.4 for positive control
group (Group 2A) and 2.9 for the dexamethasone-treated
group (Group 3).
The means of total microscopic scores for the three inter-
vention groups followed for 22 days are indicated in Fig. 2.
As indicated by the ﬁgure, the mean score of rats in Group
2A was signiﬁcantly higher than that of rats in Group 1A
(P< 0.05). The presence and severity of microscopic ﬁnd-
ings are shown in Fig. 3. When comparing the microscopic
severity scores of untreated CIA rats sacriﬁced at Day 28
with those sacriﬁced at Day 22, we observed higher sub-
scores of bone lesions, but not of cartilage lesions. Thus,
mean subscores of bone lesions at Day 22 and Day 28
were 2.9 and 5.7, respectively (P< 0.001), whereas sub-
scores referring to cartilage damage were 4.6 and 6.3, re-
spectively (P> 0.05). Total microscopic severity scores of
dexamethasone-treated animals were lower than the
scores of untreated animals, but differences did not reach
statistical signiﬁcance.
CTX-II levels in the synovial fluid and the serum. The mean
values of CTX-II in the synovial ﬂuid for the three groups
Table III
Dilution recoveries
Sample Dilution
(%)
Measured
concentration
(ng/L)
Expected
concentration
(ng/L)
Recovery
(%)
Serum I None 40.5 40.5 100
20 34.3 32.4 106
40 25.0 24.3 103
60 14.5 16.2 90
80 8.2 8.1 101
90 3.3 4.1 82
Serum II None 57.0 57.0 100
20 45.1 45.6 99
40 36.2 34.2 106
60 26.1 22.8 115
80 12.5 11.4 110
90 5.6 5.7 97
Serum III None 38.8 38.8 100
20 32.8 31.1 105
40 23.5 23.3 101
60 16.2 15.5 104
80 7.6 7.8 98
Three different serum samples were measured either undiluted
or diluted in standard buffer. The undiluted serum sample was set
to 100%. Average recovery is 99 8.2%.followed for 22 days are shown in Fig. 2. CTX-II levels in
the immunized rats (Group 2A) were markedly higher com-
pared to CTX-II levels in negative controls, i.e., Group 1A
(P< 0.0001). Although CTX-II concentration in the synovial
ﬂuid from dexamethasone-treated animals was generally
lower, differences compared with levels in untreated immu-
nized rats did not reach statistical signiﬁcance. CTX-II
concentrations in the synovial ﬂuid of untreated immu-
nized animals followed for 28 days (Group 2B) were compa-
rable with CTX-II levels of animals followed for 22 days
(Group 2A).
The corresponding values of serum CTX-II are summa-
rized in Fig. 2. The serum levels of CTX-II were also mark-
edly elevated in untreated immunized animals (Group 2A)
compared with negative controls (Group 1A, P< 0.05).
Serum CTX-II levels in dexamethasone-treated animals
(Group 3) were on an average lower than those in untreated
animals (Group 2A), but differences did not reach statistical
signiﬁcance. In addition, serum levels of CTX-II at Day
28 (Group 2B) were comparable with those at Day 22
(Group 2A).
Association between the total microscopic severity scores
of joint lesions and CTX-II. There were strong associations
Table IV
Analytical recovery for serum samples in serum CTX-II test
Sample Spiking
(ng/L)
Measured
concentration
(ng/L)
Expected
concentration
(ng/L)
Recovery
(%)
Serum IV None 28.3 28.3 100
þ Std. A (0) 14.6 14.2 103
þ Std. B (7) 16.8 17.3 97
þ Std. C (17) 19.8 22.1 90
þ Std. D (42) 31.5 34.0 93
þ Std. E (105) 58.2 63.7 91
þ Std. F (263) 119.3 138.0 86
Serum V None 66.9 66.9 100
þ Std. A (0) 34.7 33.4 104
þ Std. B (7) 38.3 36.6 105
þ Std. C (17) 40.6 41.3 98
þ Std. D (42) 49.1 53.2 92
þ Std. E (105) 76.4 83.0 92
þ Std. F (263) 135.4 157.2 86
Serum IVþ
Serum V
20þ 80% 35.9 30.7 86
40þ 60% 43.4 45.1 104
60þ 40% 50.9 54.0 106
80þ 20% 58.4 57.8 99
Serum samples were diluted 1:1 with calibrators and diluted in in-
crements of 20% in another serum sample. Average recovery is
98.0 7.0%. The corresponding average recovery for urinary as-
say is 100 11.7%.
675Osteoarthritis and Cartilage Vol. 14, No. 7between the severity of joint damage (i.e., total microscopic
severity scores) and CTX-II levels in the synovial ﬂuid
(r¼ 0.76; P< 0.0001) and the serum (r¼ 0.85;
P< 0.0001). Accordingly, there was a signiﬁcant associa-
tion between CTX-II concentrations of synovial ﬂuid and
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Fig. 2. Microscopic severity scores of joint lesions (white bars)
and CTX-II levels in synovial ﬂuid (grey bars) and serum
(black bars) samples for negative controls (Group 1), animals with
CIA (Group 2) and animals with CIA treated with dexamethasone
0.025 mg/kg/day (Group 3) at Day 22. Results are shown asmeanþ
S.E.M. *P< 0.05; ***P< 0.001 (compared with negative controls).serum (r¼ 0.83; P< 0.0001). These associations are also
illustrated in Fig. 4(AeC).
Mono-iodoacetate-induced OA
Microscopic findings. Microscopic alterations in the three
intervention groups are indicated in Fig. 5. Intra-articular in-
jection of mono-iodoacetate resulted in minimal to severe
chondrocyte necrosis, proteoglycan loss, and subchondral
bone lesions in all rats. The mean of the total severity score
of these lesions in Group 5 was signiﬁcantly higher com-
pared with that in animals of Group 4 (P< 0.001). Total se-
verity scores of doxycycline-treated rats (Group 6) were
similar to those not receiving treatment (Group 5).
CTX-II levels in synovial fluid and serum. As expected, the
monoarthritic lesion was insufﬁcient to increase serum
levels of CTX-II. However, measurements in the synovial
ﬂuid indicated elevated levels of CTX-II in the femoro-tibial
joints injected with mono-iodoacetate (Group 5) compared
with those injected with saline only (Group 4, P< 0.05).
CTX-II levels in the synovial ﬂuid from doxycycline-treatedFig. 3. The microscopic ﬁndings in the femoro-tibial (A, C) and tarsal (B, D) joints from an animal with CIA (right panel) with reference to a neg-
ative control animal (left panel). Sections were stained with Safranin-O for visualizations of proteoglycans (2 magniﬁcation). Lesions illus-
trated are (1) inﬂammation; (2) bone resorption; (3) osteophyte; and (4) cartilage damage. Each of these was graded on a scale from 0 to
5. The femoro-tibial joint illustrated in Panel C received the following subscores: 3 for inﬂammation; 4 for bone resorption; 1 for osteophyte
and 3 for cartilage damage. The tarsal joint illustrated in Panel D from the same animal received a subscore of 4 for all parameters. Thus,
the total score was 27. The animals from the negative control group illustrated in Panels A and B received a total score of 0. The serum
CTX-II values for the negative control and the untreated CIA rat were 26.9 pg/ml and 163.2 pg/ml, respectively. The corresponding levels
of CTX-II in the synovial ﬂuid were 7.2 pg/ml and 274.8 pg/ml, respectively.
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Fig. 4. Association between CTX-II level and the total microscopic severity score of joint lesions in the CIA model. Means of total microscopic
severity scores in tertiles of serum CTX-II at Day 22 (Panel A), means of total microscopic severity scores in tertiles of CTX-II in the synovial
ﬂuid at Day 22 (Panel B), and means of serum CTX-II in tertiles of CTX-II in the synovial ﬂuid at Day 22 (Panel C). Results are shown as
meanþ S.E.M. Cut-off values between the tertiles of serum CTX-II were 36 ng/L (33rd percentile) and 160 ng/L (66th percentile). The respec-
tive values for CTX-II in the synovial ﬂuid were 8 ng/L (33rd percentile) and 249.6 ng/L (66th percentile).animals were not signiﬁcantly different from those in un-
treated animals.
Association between the total microscopic severity scores
of joint lesions and CTX-II. CTX-II in the synovial ﬂuid
showed statistically signiﬁcant correlations with the total
microscopic severity scores of joint lesions (r¼ 0.53;
P< 0.0001). The linear association between these parame-
ters is also illustrated in Fig. 6.
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Fig. 5. Means of themicroscopic severity score of joint lesions (white
bars) and CTX-II in the synovial ﬂuid (grey bars) in control animals
(Group 4), animals with MIA (Group 5) and animals with MIA treated
with doxycycline 10 mg/kg/day (Group 6) at Day 22. Results are
shown as meanþ S.E.M. *P< 0.05, **P< 0.01.Discussion
In the present study, we have shown that F4601 is spe-
ciﬁc for the EKGPDP sequence, which is an epitope exclu-
sively present in collagen type II. The F4601 antibody
similar to the F26 antibody16, which is used in the urinary
CTX-II (CartiLaps) assay binds to the free C-terminal Pro-
line. However, whereas the urinary CTX-II assay is a com-
petitive ELISA that recognizes monomer and cross-linked
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Fig. 6. Association between CTX-II level in the synovial ﬂuid and
the microscopic severity scores of joint lesions in the MIA model.
Results are shown as meanþ S.E.M. Cut-off values between the ter-
tiles of CTX-II were 18 ng/L (33rd percentile) and 28.4 ng/L (66th
percentile).
677Osteoarthritis and Cartilage Vol. 14, No. 7dimer CTX-II, the herein described assay is a sandwich as-
say that targets dimer CTX-II only.
An important question is whether the CTX-II epitope is
generated during enzymatic degradation of hyaline carti-
lage in vivo. Chondrocytes and monocytes/macrophages
can mutually induce alterations in the expression of cata-
bolic enzymes, in particular, enzymes of the MMP family.
MMP-9 and MMP-13 have recently been implicated in car-
tilage degradation of RA patients28,29. When articular
explants were subjected to enzymatic degradation by
MMP-9 or MMP-13, we found strong signals detected by
the assay indicating the generation of epitopes. When inhib-
iting MMPs, the generation of epitopes was no longer
present. Collectively, these ﬁndings suggest that the Pre-
clinical Serum CTX-II assay detects peptide fragments,
which are generated during enzymatic processes with direct
in vivo relevance.
The Preclinical Serum CTX-II assay demonstrated a high
degree of precision and reproducibility with inter- and intra-
assay CVs below 8.0%, with good linearity. Furthermore,
when the calibrator was spiked into a serum sample or
when one serum sample was spiked into another serum
sample, the antigen was measured with recovery rates
close to 100%, indicating that the antibody has similar afﬁn-
ity for the calibrator and the authentic antigen in the serum.
Regarding these technical details, the performance of the
serum assay is comparable with those provided by the pre-
viously introduced urinary CTX-II assay16.
Our in vivo experiments investigated whether measuring
CTX-II in serum and synovial ﬂuid samples can provide in-
formation about the structural integrity of articular cartilage
in two models of arthritis. The main ﬁndings were as follows:
(1) CTX-II levels in the synovial ﬂuid showed signiﬁcant cor-
relation with the total microscopic severity scores of joint le-
sions in both models, (2) serum CTX-II showed strong
association with the respective total microscopic severity
scores in the CIA model as well as with CTX-II levels in
the synovial ﬂuid; no similar associations were revealed in
the MIA model, and (3) differences in CTX-II in the synovial
ﬂuid between untreated and treated animals followed the
same pattern as shown by differences in the total micro-
scopic severity scores of joint damage at the end of the
treatment period in both arthritis models (this was also
true for serum CTX-II levels in the CIA model). Collectively,
these ﬁndings suggest that the Preclinical Serum CTX-II
ELISA could provide a reliable non-invasive assessment
of disease progression and therapeutic responses to candi-
date drugs with chondroprotective potentials.
CIA in rodents shares histological and immunological
features of human RA and therefore is currently one of
the most preferred experimental models1,3,4,30. Several
markers, such as COMP, C2C, and urinary CTX-II have
been tested for their utility to monitor cartilage damage in
the CIA model. However, as reported by Larsson et al.11
‘‘there was only a relatively limited increase in the serum
levels of COMP at day 21 when the rats had already devel-
oped high arthritis scores, whereas the main increase in se-
rum levels of COMP appeared between days 21 and 28’’.
Measurements of C2C levels in the CIA model also failed
to show signiﬁcant differences between positive and nega-
tive control groups31. In the present study, the Preclinical
Serum assay detected marked and statistically signiﬁcant
increases in CTX-II both in serum and in synovial ﬂuid sam-
ples collected at Day 22. The CTX-II measurements could
not only discriminate control and diseased groups, but could
also give quantitative information regarding the severity of
joint damage. This latter feature was indicated bya signiﬁcant correlation between total microscopic severity
scores of joint lesions and the level of CTX-II in the serum
or the synovial ﬂuid. Thus, these results suggest that the
herein introduced assay allowing measurements of CTX-II
in synovial ﬂuid and/or serum samples provides a useful di-
agnostic tool for the non-invasive assessment of cartilage
status in the CIA model.
The CIA model is often used to evaluate the chondropro-
tective effects of disease-modifying agents. For example,
corticosteroids were repeatedly shown to provide therapeut-
ical beneﬁts in inﬂammatory joint diseases12,30,32. Our ﬁnd-
ings indicated lower microscopic scores and lower levels of
CTX-II in the synovial ﬂuid and serum of animals receiving
dexamethasone treatment. However, when compared to
previously published data20, the inhibition achieved was no-
tably weaker, likely due to insufﬁcient dosing. This was also
indicated by the lack of anti-inﬂammatory effects as as-
sessed by the impact on redness and swelling of the joints.
Nevertheless, CTX-II levels adequately reﬂected the mod-
est attenuation of structural damage by the treatment.
Doxycycline, similar to more speciﬁc inhibitors of MMPs,
was found to provide therapeutical beneﬁts in the MIA
model33. The treatment applied in the present study failed
to elicit effective prevention of accelerated cartilage turn-
over and the consequent structural alterations. The lack of
efﬁcacy could be due to an imbalance between the intensity
of disease and the selected dose or overall duration of the
treatment. Notwithstanding this failure, the lack of efﬁcacy
was again adequately reﬂected by the CTX-II measurement
in the synovial sample, further emphasizing the utility for es-
timating structural status of articular cartilage.
Circulating levels of CTX-II showed poor to no associa-
tion with the severity of joint lesions in the MIA model.
This can be explained by differences in the pathogenesis
of the joint disease. In the CIA model, animals are immu-
nized with bovine collagen type II, which generates a sys-
temic inﬂammatory response and utilization of an array
of enzymatic processes to eliminate collagen type II. In
contrast, in the MIA model, only a monoarthritic lesion is
provoked by local metabolic paralysis of chondrocytes.
The difference in the intensity of the two forms of arthritis
is also indicated by the observation that CTX-II levels in
the synovial ﬂuid were w10-fold higher in rats with CIA
compared with levels in rats with MIA. These differences
in intensity and extent (polyarthritis vs monoarthritis) of
the two joint diseases seem to provide a plausible explana-
tion to why serum levels are more informative in the CIA
model.
The results of the study suggest that the herein intro-
duced assay provides a useful diagnostic tool for measuring
CTX-II in both serum and synovial ﬂuid samples from ro-
dents, which in turn might facilitate the non-invasive assess-
ment of articular cartilage status in these animals.
Importantly, whereas CTX-II in the synovial ﬂuid adequately
reﬂected cartilage status of the affected joint in both models,
the utility of serum measurements seems to be limited to
systemic forms of joint diseases. These ﬁndings call for
intervention studies investigating whether early, treatment-
induced changes in serum CTX-II can predict the chondro-
protective potentials of candidate drugs.
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